Deletion of Neuropilin 1 from Microglia or Bone Marrow-Derived Macrophages Slows Glioma Progression

Jeremy Tetsuo Miyauchi1, Michael D Caponegro1, Danling Chen1

  • 1Department of Pharmacological Sciences, Stony Brook University, Stony Brook, New York.

Cancer Research
|November 4, 2017
PubMed

Insights

Targeting neuropilin-1 (Nrp1) in glioma-associated microglia and macrophages (GAM) reprogrammed their function, reducing tumor growth and enhancing anti-tumor immunity. Manipulating Nrp1 in these cells offers a potential therapeutic strategy for glioma.

Area of Science:

  • Immunology
  • Neuro-oncology
  • Cancer Biology

Background:

  • Glioma-associated microglia and macrophages (GAM) are key cellular components in high-grade gliomas.
  • Tumor-derived cytokines reprogram GAM to support tumor growth and suppress anti-tumor immune responses.
  • Neuropilin-1 (Nrp1) is a transmembrane receptor that influences GAM immune polarization.

Purpose of the Study:

  • To investigate the role of neuropilin-1 (Nrp1) in modulating glioma-associated microglia and macrophages (GAM).
  • To determine if manipulating Nrp1 expression in macrophages can confer resistance to glioma development.

Main Methods:

  • Generated Nrp1-deficient bone marrow-derived macrophages (BMDM) and bone marrow chimeras.
  • Replaced peripheral macrophage populations in wild-type mice with Nrp1-depleted BMDM.
  • Analyzed glioma volumes, neoangiogenesis, immune cell infiltration (CTLs), and GAM phenotype in Nrp1-manipulated mice.

Main Results:

  • Mice with Nrp1-depleted peripheral macrophages or Nrp1-deficient microglia showed resistance to glioma development.
  • Tumors in these mice exhibited decreased volumes, reduced vascularity, and increased cytotoxic T lymphocyte (CTL) infiltration.
  • Nrp1-depleted GAM adopted a more anti-tumorigenic phenotype compared to wild-type GAM.

Conclusions:

  • Neuropilin-1 (Nrp1) in macrophages and microglial cells is a critical regulator of tumor neovascularization and immunosuppression in gliomas.
  • Targeting Nrp1 in GAM can reprogram their function, promoting anti-tumor immunity and inhibiting glioma progression.
  • This highlights Nrp1 as a potential therapeutic target for glioma treatment.

Related Concept Videos